Filtration, separation and purification specialist, Pall, has announced a strategic partnership between its Pall Biotech business using and Aetos Biologics — a biosimilar cell line development company.
Strategic alliance
Under the terms of the partnership, the companies will collaborate to offer biosimilar manufacturing solutions to the global biosimilars market. Pall Biotech will provide access to next generation bioprocess equipment and consumables to enable efficient biosimilar production. Aetos Biologics will provide high quality/high-titre cell lines, and scalable manufacturing processes.
“Biosimilars are a replication of a successful biopharmaceutical product. While they are much less expensive than innovator molecules, the complexities in their development make it critical to work with the right equipment and service providers,” said Mario Philips, VP & general manager at Pall Biotech. “We are excited to partner with the Aetos Biologics team to advance the market impact of biosimilars and deliver lower priced, high-quality options to end users.”
“Our team is constantly working to optimise a growing pipeline of high-yield biosimilars with outstanding quality,” said Amita Goel, founder and CEO of Aetos Biologics. “Through this strategic partnership with Pall Biotech, we can ensure that the exceptional quality we achieve in scaled-up processes is efficiently transferred and reproduced by the client.”